Cue Biopharma adds Phase 2 anti-IgE asset in $691.5M deal

Cue Biopharma said on April 30, 2026, that it licensed Ascendant-221, a Phase 2 anti-IgE monoclonal antibody for allergic diseases, from Ascendant Health Sciences in a deal worth about $691.5 million, including a $15 million upfront payment and up to $676.5 million in development, regulatory, and commercial milestones. Cue receives global rights outside mainland China, Hong Kong, Macau, and Taiwan, while Ascendant-221 is already being studied in a Phase 2 chronic spontaneous urticaria trial in China. Cue said it plans to start a global Phase 2b trial in food allergy after reviewing data from that China study, which it expects in the second half of 2026. The asset was formerly known as UB-221. (cuebiopharma.gcs-web.com)

Why it matters: For veterinary professionals, this isn’t an animal health story yet, but it’s a useful signal about where allergy drug development is heading. Anti-IgE therapy is already established in human medicine, and the commercial interest around food allergy and other IgE-mediated disease continues to grow after the FDA’s 2024 approval of omalizumab for reducing allergic reactions from accidental exposure to multiple foods. Ascendant-221’s pitch is differentiation: Cue is emphasizing a dual mechanism, durable free-IgE suppression beyond 12 weeks after a single dose in Phase 1, and the possibility of less frequent dosing than current standards of care. That kind of platform evolution is worth watching because dermatology, atopy, and food hypersensitivity remain active areas of comparative interest across human and veterinary immunology. (fda.gov)

What to watch: The next key inflection point is Phase 2 chronic spontaneous urticaria data expected in 2H 2026, which will likely determine how aggressively Cue advances the planned global food allergy study. (cuebiopharma.gcs-web.com)